<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03129503</url>
  </required_header>
  <id_info>
    <org_study_id>1.0</org_study_id>
    <nct_id>NCT03129503</nct_id>
  </id_info>
  <brief_title>Optical Coherence Tomography in Acute Coronary Syndrome</brief_title>
  <acronym>OPTICO-ACS</acronym>
  <official_title>Optical Coherence Tomography in Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Berlin Institut of Health (BIH), Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The OPTICO-ACS- study program - combining for the first time in vivo characterization of the
      ACS-causing &quot;culprit lesion&quot; by intracoronary imaging technique with optical coherence
      tomography (OCT) and molecular analysis of immune-cells derived from the culprit coronary
      thrombus and biochemical analyses in patients with acute-coronary-syndrome (ACS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using a translational scientific approach the study aims to (a) get a better insight into the
      different pathophysiological processes in both clinical settings - plaque rupture (RFC) and
      plaque-erosion (IFC) with focus on to the inflammatory process and molecular mechanisms (b)
      identify special signatures including clinical and biochemical markers as biomarkers subject
      to different culprit plaques types and (c) to test its prognostic implications in patients
      after ACS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Major adverse cardiovascular Events (MACCE)</measure>
    <time_frame>2 years after ACS</time_frame>
    <description>powered</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rehospitalization Rate for Angina pectoris</measure>
    <time_frame>2 years after ACS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular Events (MACCE)</measure>
    <time_frame>30 days, 90 days, 12 months and 5 years after ACS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intima /media thickness</measure>
    <time_frame>Day 90 after ACS</time_frame>
    <description>by sonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global and regional left-ventricular systolic and diastolic function</measure>
    <time_frame>After ACS and 90 days after ACS</time_frame>
    <description>by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of angina</measure>
    <time_frame>at day 90,12 and 24 months after ACS</time_frame>
    <description>by Seattle Angina questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse-wave-velocity (PWV), Augmentation index (AI) and Sub-endocardial Viability Ratio (SEVR).</measure>
    <time_frame>Day 90 after ACS</time_frame>
    <description>by SphygmoCor system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion Coverage</measure>
    <time_frame>within 6 weeks to 3 months</time_frame>
    <description>by OCT</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">414</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>STEMI - ST Elevation Myocardial Infarction</condition>
  <condition>NSTEMI - Non-ST Segment Elevation MI</condition>
  <condition>Atherosclerosis, Coronary</condition>
  <arm_group>
    <arm_group_label>Acute coronary syndrome (ACS)</arm_group_label>
    <description>Patients with STE- or NSTE-ACS (acute coronary syndrome)</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and coronary thrombus
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        ACS Patients at Charité University Hospital including all sites

          -  Campus Benjamin Franklin (CBF)

          -  Campus Virchow Klinikum (CVK)

          -  Campus Mitte (CCM)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and Women (aim: consecutive)

          2. Age 18 to 85 years old.

          3. ACS as trigger event - (ESC guidelines) being:

               1. Acute cardiac chest pain or angina equivalent consistent with moderate to
                  high-risk unstable angina or myocardial infarction, lasting more than 10 minutes
                  duration during 72 hours before invasive examination AND

               2. Evidence for ACS requiring catheterization documented by a) elevated enzymes
                  (CK-MB or hs-Troponin I/T &gt; 99th percentile or in-/decrease) AND/OR

               3. ECG with ST-depression &gt;1mm in 2 or more contiguous leads after the J-point
                  AND/OR transient ST-elevation &gt;1mm in 2 or more contiguous leads lasting &lt;30 min
                  OR c) STE-ACS with onset &lt; 24 hours previously and chest pain &gt;30 min
                  ST-elevation &gt;1mm in 2 or more contiguous leads or new left bundle block.

          4. Written informed consent

          5. Patients must have at least coronary one-vessel disease with one angiographically
             detectable &quot;culprit lesion&quot; (or in case of more &gt; 1 lesion all lesions have to be in
             one &quot;culprit vessel&quot;) in a native coronary vessel requiring PCI. Identification of
             this lesion as the &quot;culprit lesion&quot; has to be in line with other non-invasive findings
             (ECG-leads; regional wall motion abnormalities in echocardiography). Other
             &quot;non-culprit-lesions&quot; are allowed to have significant stenosis requiring
             interventional revascularization in a staged procedure.

        Exclusion Criteria:

          1. Active pregnancy.

          2. Active sepsis.

          3. Acute psychotic disease.

          4. Known systolic heart failure with left-ventricular ejection fraction (LV-EF≤ 30 %).

          5. Cardiogenic shock or heart failure requiring intubation, inotropes; diuretics or
             mechanical circulation support.

          6. Refractory ventricular arrhythmia requiring pharmacologic or defibrillator therapy.

          7. Patients who had received heart transplantation or any other organ transplant or are
             on waiting list.

          8. Renal insufficiency with serum-creatinine ≥ 1.5 mg/dl.

          9. Patients with other medical illness (i.e. cancer) or recent history of substance
             abuse, that may cause non-compliance with the investigational plan, confound the data
             interpretation or is associated with an anticipated limited life-expectancy less than
             one year.

         10. Prior participation in this study or in other investigational studies, that have not
             reached its primary endpoint.

         11. Unprotected left main- CAD with ≥ 50% stenosis.

         12. ACS with culprit lesion in a bypass graft or ACS caused by stent-thrombosis.

         13. Extent and severity of CAD is such that investigator believes it is likely that bypass
             surgery will be required within 1 year of enrollment.

         14. No suitable anatomy of &quot;culprit lesion&quot; for OCT:

               -  severe calcification or extreme tortuosity of &quot;culprit lesion&quot;.

               -  culprit lesion with very distal location.

               -  infarct vessels with an diameter &gt; 4 mm or &lt; 2 mm.

               -  STE-ACS: &quot;No-reflow&quot; (TIMI 0-I) after thrombus aspiration/slight pre- dilatation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>David M Leistner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Charite - University Medicine Berlin - Department for cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulf Landmesser, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Charite - University Medicine Berlin - Department for cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David M Leistner, MD</last_name>
    <phone>004930450513702</phone>
    <email>david‐manuel.leistner@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Gössinger</last_name>
    <phone>004930450643547</phone>
    <email>anne.goessinger@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charite University Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henryk Dreger, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bernd Hewing, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite University Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David M Leistner, MD</last_name>
      <phone>004930450513702</phone>
      <email>david-manuel.leistner@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charite University Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carsten Tschöpe, MD</last_name>
    </contact>
    <investigator>
      <last_name>Frank Edelmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florian Krackhardt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2017</study_first_submitted>
  <study_first_submitted_qc>April 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2017</study_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>David Manuel Leistner</investigator_full_name>
    <investigator_title>PD Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Optical coherence tomography (OCT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

